Nipah [strain Bangladesh] vaccine is under clinical development by Public Health Vaccines and currently in Phase I for Viral Infections. According to GlobalData, Phase I drugs for Viral Infections have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nipah [strain Bangladesh] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nipah [strain Bangladesh] vaccine overview
Vaccine (rVSV-Nipah vaccine) is under development for the prevention of Nipah virus infections. The vaccine candidate is a live, attenuated recombinant vesicular stomatitis virus (rVSV) vector that expresses the glycoprotein (G) of the Nipah virus (Bangladesh strain). It is administered through intramuscular route.
For a complete picture of Nipah [strain Bangladesh] vaccine’s drug-specific PTSR and LoA scores, buy the report here.